William Rascan - Nova Mentis CEO Pres
| NMLSF Stock | USD 0.03 0 6.14% |
Insider
William Rascan is CEO Pres of Nova Mentis Life
| Age | 57 |
| Phone | 778 819 0244 |
| Web | https://www.novamentis.ca |
Nova Mentis Management Efficiency
The company has return on total asset (ROA) of (0.5228) % which means that it has lost $0.5228 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.8948) %, meaning that it generated substantial loss on money invested by shareholders. Nova Mentis' management efficiency ratios could be used to measure how well Nova Mentis manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| David Hovland | Eledon Pharmaceuticals | N/A | |
| Gregory Flesher | Eledon Pharmaceuticals | 54 | |
| Magnus Halle | GH Research PLC | 27 | |
| William Lis | Jasper Therapeutics | 60 | |
| Jeffrey Bornstein | Eledon Pharmaceuticals | N/A | |
| Carol Zoltowski | Jasper Therapeutics | 74 | |
| Jeet MBA | Jasper Therapeutics | N/A | |
| Susan Prohaska | Jasper Therapeutics | N/A | |
| Andrew Slee | Protagenic Therapeutics | 74 | |
| Robert MD | Protagenic Therapeutics | 73 | |
| Theis MD | GH Research PLC | 48 | |
| Julie ACA | GH Research PLC | 38 | |
| Florian M | GH Research PLC | 55 | |
| Eric Tse | Sino Biopharmaceutical Ltd | 27 | |
| Kevin MD | Jasper Therapeutics | 53 | |
| David Lovejoy | Protagenic Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.89 | |||
| Return On Asset | -0.52 |
Nova Mentis Life Leadership Team
Elected by the shareholders, the Nova Mentis' board of directors comprises two types of representatives: Nova Mentis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nova. The board's role is to monitor Nova Mentis' management team and ensure that shareholders' interests are well served. Nova Mentis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nova Mentis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Rascan, CEO Pres | ||
| Kelly Pladson, Co Sec | ||
| Stephen Glazer, Chief Director | ||
| Jacqueline McConnell, COO Director |
Nova Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Nova Mentis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.89 | |||
| Return On Asset | -0.52 | |||
| Current Valuation | 5.46 M | |||
| Shares Outstanding | 143.47 M | |||
| Shares Owned By Insiders | 11.73 % | |||
| Shares Owned By Institutions | 0.01 % | |||
| Price To Book | 7.68 X | |||
| Price To Sales | 5,731 X | |||
| Gross Profit | (5.44 K) | |||
| EBITDA | (2.93 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in Nova Pink Sheet
Nova Mentis financial ratios help investors to determine whether Nova Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nova with respect to the benefits of owning Nova Mentis security.